Key result
Drug-eluting stents lowered 18-month TVR vs bare-metal stents and reduced cardiac death/MI in small vessels or bypass grafts.
Why the study?
It was unknown which patients benefit most from drug-eluting stents compared with bare-metal stents regarding long-term clinical outcomes.
Does drug-eluting stent (DES) use reduce cardiac death/myocardial infarction and non-MI-related target-vessel revascularization compared to bare-metal stents (BMS) in specific patient subgroups undergoing angioplasty?
RCT (n=826)
2:1 randomization to DES vs. BMS
Does drug-eluting stent (DES) use reduce cardiac death/myocardial infarction and non-MI-related target-vessel revascularization compared to bare-metal stents (BMS) in specific patient subgroups undergoing angioplasty?
Answers are grounded in this paper and cite their sources.
Long-term clinical benefit of drug-eluting stents over bare-metal stents appears restricted to patients undergoing angioplasty of small vessels (<3.0 mm) or bypass grafts, whereas patients with large native vessel stenting may experience increased late cardiac death or MI.
AIM: It is unknown which patients benefit most from drug-eluting stents (DES) against bare-metal stents (BMS) in a long-term clinical outcome. METHODS AND RESULTS: To address this question, data from 826 consecutive patients with angioplasty, randomized 2:1 to DES vs. BMS, with an 18-month follow-up for cardiac death/myocardial infarction (MI) and non-MI-related target-vessel revascularization (TVR) were analysed for interactions between stent type and patient/vessel characteristics predicting events. Rates of 18-month TVRs were lower with DES vs. BMS use (7.5 vs. 11.6%, P = 0.05), but similar for both stents regarding cardiac death/MI (DES, 8.4%; BMS, 7.5%; P = 0.70). Significant interactions between stent type and two multivariable event predictors were identified: small stents (<3.0 mm) and bypass graft stenting. In these patient groups together (n = 268, 32%), DES reduced non-MI-related TVR (HR = 0.44; P = 0.02) and cardiac death/MI (HR = 0.44; P = 0.04), whereas in the other 558 patients (68%) TVR rate was similar (HR = 0.75; P = 0.38) and cardiac death/MI rate increased after DES (HR = 2.07; P = 0.05). CONCLUSION: Patients with angioplasty of small vessels or bypass grafts seem to benefit from DES use, in long-term outcome, in contrast to patients with large native vessel stenting where there might even be late harm. Still, this hypothesis needs to be tested prospectively.
No takes yet. Share an insight, caveat, or question.
Rocca et al. (2007) conducted an RCT in patients undergoing angioplasty (n=826). Drug-eluting stents (DES) vs. Bare-metal stents (BMS) was evaluated on Non-MI-related target-vessel revascularization (TVR) and cardiac death/myocardial infarction (MI) at 18 months (p=0.05). Drug-eluting stents lowered 18-month TVR vs bare-metal stents and reduced cardiac death/MI in small vessels or bypass grafts.
Synapse has enriched 10 related papers. Consider them for comparative context: